Global Medical REIT Inc. (NYSE:XRN – Get Free Report) Director Charles Fitzgerald purchased 27,600 shares of the stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $35.94 per share, with a total value of $991,944.00. Following the acquisition, the director directly owned 124,893 shares in the company, valued at $4,488,654.42. This represents a 28.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Global Medical REIT Price Performance
XRN stock opened at $36.43 on Thursday. The company has a current ratio of 0.68, a quick ratio of 0.68 and a debt-to-equity ratio of 1.68. Global Medical REIT Inc. has a twelve month low of $29.05 and a twelve month high of $39.93. The business has a 50 day simple moving average of $36.57 and a 200-day simple moving average of $35.79. The company has a market capitalization of $482.33 million, a P/E ratio of 9.79 and a beta of 1.09.
Global Medical REIT (NYSE:XRN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $4.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $3.95. Global Medical REIT had a net margin of 36.82% and a return on equity of 13.74%. The business had revenue of $39.75 million for the quarter. As a group, equities analysts anticipate that Global Medical REIT Inc. will post 3.06 EPS for the current year.
Hedge Funds Weigh In On Global Medical REIT
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on XRN. Wall Street Zen cut shares of Global Medical REIT from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Compass Point reissued a “neutral” rating and set a $38.00 target price (down from $50.00) on shares of Global Medical REIT in a research report on Thursday, May 7th. Citizens Jmp boosted their price target on Global Medical REIT from $40.00 to $42.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 26th. Zacks Research upgraded shares of Global Medical REIT to a “hold” rating in a research note on Wednesday, July 22nd. Finally, Weiss Ratings downgraded shares of Global Medical REIT from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $40.25.
Check Out Our Latest Report on Global Medical REIT
Global Medical REIT Company Profile
Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.
Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.
Read More
- Five stocks we like better than Global Medical REIT
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Global Medical REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Medical REIT and related companies with MarketBeat.com's FREE daily email newsletter.
